Zacks: Analysts Anticipate Zymeworks (ZYME) Will Post Earnings of -$0.69 Per Share
Analysts forecast that Zymeworks (NYSE:ZYME) will announce earnings of ($0.69) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Zymeworks’ earnings, with estimates ranging from ($0.69) to ($0.68). Zymeworks reported earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 9.5%. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 14th.
On average, analysts expect that Zymeworks will report full year earnings of ($2.88) per share for the current year, with EPS estimates ranging from ($3.11) to ($2.64). For the next fiscal year, analysts forecast that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($3.06) to ($1.75). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Zymeworks.
Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Wednesday, March 14th. The company reported $1.28 earnings per share (EPS) for the quarter. Zymeworks had a negative net margin of 30.41% and a negative return on equity of 16.07%. The business had revenue of $50.07 million for the quarter.
ZYME stock opened at $17.34 on Tuesday. Zymeworks has a 52-week low of $16.84 and a 52-week high of $17.58. The company has a market cap of $421.95 million and a PE ratio of -30.42.
A number of institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC increased its stake in Zymeworks by 6.4% in the 4th quarter. Perceptive Advisors LLC now owns 777,497 shares of the company’s stock valued at $5,549,000 after buying an additional 46,729 shares during the period. PenderFund Capital Management Ltd. acquired a new position in Zymeworks in the 1st quarter valued at approximately $5,360,000. Finally, Stanley Laman Group Ltd. acquired a new position in Zymeworks in the 1st quarter valued at approximately $439,000. Hedge funds and other institutional investors own 8.69% of the company’s stock.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.